Joseph T. Tseng's Biography

Joseph T. Tseng, Associate Professor, National Cheng-Kung University

Dr. Joseph T. Tseng is an Associate Professor of Biotechnology and Bioscience industry at the Cheng-Kung University, Taiwan. He also named as the deputy director of Center of Genomic Medicine, NCKU to lead the service team of NGS and molecular diagnosis. Prior to his NCKU appointment, he worked at biotech company to develop diagnosis kit. He received his B.S degree in Electrical Engineering from National Chiao-Tung University and Ph.D degree in Life Science from national Tsing-Hua University. Therefore, Dr. Tseng not only familiar with wet-bench work, but also the dry-bench work. His research is focusing on translational regulation mechanism, including IRES, uORF and specialized ribosome. Besides, he is also developing novel genome technologies to accelerate the cancer biomarker discovery.

Translatome Analysis by NGS: Filling the Gap Between Transcriptome and Proteome Results in Biomarker Discovery

Thursday, 1 December 2016 at 13:30

Add to Calendar ▼2016-12-01 13:30:002016-12-01 14:30:00Europe/LondonTranslatome Analysis by NGS: Filling the Gap Between Transcriptome and Proteome Results in Biomarker DiscoveryNext Generation Sequencing Asia 2016: Clinical Applications in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com

Ribosome profiling or ribo-seq is a new technique that provide genome-wide information on protein synthesis in vivo, and filled the technological gap existing between our abilities to quantify the transcriptome and the proteome. The applications of ribosome profiling were used to identify the translation start sites, the distribution and the speed of translating ribosome, and to study the effects of microRNAs on translation. This technology already dramatically change our understanding of translational control. In my lab, we have successfully established and modified this technology to get a more high quality data with lower cost. And the translatome result of different kinds of colon polyps were analyzed. From the results, we identity several good biomarkers for further validation and highlight the importance of Ribo-Seq technology in biomarker discovery.

Add to Calendar ▼2016-12-01 00:00:002016-12-02 00:00:00Europe/LondonNext Generation Sequencing Asia 2016: Clinical ApplicationsNext Generation Sequencing Asia 2016: Clinical Applications in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com

#NGSCA2016 Tweets

Corporate Sponsors